Taking a BiTE out of Multiple Myeloma

By Gina Shaw Kirollos Hanna, PharmDWhen teclistamab-cqyv (Tecvayli, Janssen/Johnson & Johnson) entered the multiple myeloma market at the end of 2022, it signaled the beginning of a new treatment era. For patients who had exhausted four or more prior lines of therapy, the bispecific T-cell engager (BiTE) delivered response rates that the field had never seen before.“These bispecifics have brought an unprecedented therapeutic to our multiple myeloma patients,” said Kirollos Hanna,